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Abstract
Background: Various angiogenic regulators are involved in angiogenesis cascade. Transcription factor Ets-1 plays
important role in angiogenesis, remodeling of extracellular matrix, and tumor metastasis. Ets-1 target genes
involved in various stages of new blood vessel formation include angiopoietin, matrix metalloproteinases (MMPs)
and the protease inhibitor maspin.
Methods: We used immunohistochemistry (IHC) to detect the expression of Ets-1, angiopoietin-2 (Ang-2) and
maspin in ovarian tumor and analyzed the relationship between the expression of these proteins and the clinical
manifestation of ovarian cancer.
Results: Ets-1 expression was much stronger in ovarian cancer compared to benign tumors, but had no significant
correlation with other pathological parameters of ovarian cancer. However, Ang-2 and maspin expression had no
obvious correlation with pathological parameters of ovarian cancer. Ets-1 had a positive correlation with Ang-2
which showed their close relationship in angiogenesis. Although microvessel density (MVD) value had no
significant correlation with the expression of Ets-1, Ang-2 or maspin, strong nuclear expression of maspin appeared
to be correlated with high grade and MVD.
Conclusions: The expression of Ets-1, Ang2 and maspin showed close relationship with angiogenesis in ovarian
cancer and expression of maspin appeared to be correlated with high grade and MVD. The mechanisms
underlying the cross-talk of the three factors need further investigations.
Background
Ovarian cancer is the sixth most common cancer and the
sixth most frequent cause of cancer death in women. It is
the leading cause of death from gynecologic cancer in
w o m e ni ni n d u s t r i a l i z e dc o u n t r i e s .T h ei n c i d e n c eo f
ovarian carcinoma appears to be increasing in western
countries, as evidenced by a 30% rise in incidence and a
18% rise in death rate in the United States. The largely
unchanged mortality rate from ovarian carcinoma is due
to its late clinical appearance, with two-thirds of the
patients being diagnosed as stage III or IV disease [1].
Angiogenesis is the process of formation of blood vessels
from pre-existing ones [2]. Without angiogenesis tumor
expansion cannot proceed beyond 1-2 mm since tumor
proliferation is severely limited by nutrient supply to, and
waste removal from, the tumor into the surrounding
medium. Therefore, angiogenesis is a crucial factor in the
progression of solid tumors and metastases, including
epithelial ovarian cancer [3]. Angiogenesis is a complex
process which is regulated by the balance between angio-
genic activators and inhibitors. Angiogenic factors are pro-
duced by various kinds of cells, including angiogenic
activators such as transforming growth factors a and b
(TGFa,T G F b), vascular endothelial growth factor
(VEGF), fibroblast growth factor-2 (FGF-2), platelet-
derived growth factor (PDGF), tumor necrosis factor a
(TNF-a), prostaglandin E2 and Interleukin 8. The inhibi-
tors include Thrombospondin 1(TSP-1), Angiopoietin
(Angs), and endostatin [4]. Accumulating evidence
demonstrates that the cooperation between VEGF and
Angs plays an important part in angiogenesis [5].
Various angiogenic regulators are involved in the cas-
cade of angiogenesis. Recent evidence suggests that the
Ets family of transcription factors play an important role
in angiogenesis. Ets-1 is the first member of the family
implicated in angiogenesis, remodeling of extracellular
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any medium, provided the original work is properly cited.matrix (ECM), and tumor cell metastasis [6]. Ets-1 target
genes involve in various stages of new blood vessel
formation include vascular endothelial growth factor
receptor (VEGF-R), matrix metalloproteinases (MMPs)
and the protease inhibitors maspin [7]. Immunohisto-
chemical staining demonstrated that Ets-1 was expressed
in vascular endothelial cells and cancer cells of ovarian
cancer [8]. Furthermore, Ets-1 has been suggested as a
prognostic factor for ovarian cancer since there was a sig-
nificant correlation between microvessel counts, survival
rate and Ets-1 level in ovarian cancer [9].
Up to now, four members of Angs family have been
identified including Ang-1, Ang-2, Ang-3 and Ang-4,
and the receptors of Angs are called “Ties”.T h e yp l a y
different roles in angiogenesis: Ang-1 and Ang-4 are
agonist ligands for Tie2 and induce tyrosin phosphoryla-
tion of Tie2, while Ang-2 and Ang-3 are antagonist
ligands. They bind to Tie2 without inducing tyrosin
phosphorylation, thus blocking the signal transduction
which is essential for angiogenesis, recruitment of peri-
cytes and the eventual hematopoiesis [6]. Ang-2 was ori-
ginally thought to be a competitive factor for Ang-1,
however, a recent study revealed that Ang-2 functioned
as an agonist when Ang-1 was absent or as a dose-
dependent antagonist when Ang-1 was present [10]. In
adult, the process of angiogenesis including tumor for-
mation is currently understood as follows: angiogenesis
is primarily mediated by VEGF, which promotes the
proliferation and migration of endothelial cells and tubal
formation; subsequently, Ang-1 leads to vessel matura-
tion and stabilization in physical situations. However,
such stabilized vessel can be destabilized by Ang-2, and
in the presence of VEGF Ang-2 induces proliferation of
vascular endothelial cells, disintegration of basal matrix
and promotes cellular migration; in the absence of
VEGF, vessel regression would occur due to destabiliza-
tion effect of endothelial tubal formation mediated by
Ang-2 [11]. Therefore, the balance of at least two sys-
tems (VEGF-VEGFR and Ang-tie) regulates vessel for-
mation and regression together with natural angiogenic
inhibitors [3].
Maspin, a serine protease inhibitor in the serpin
superfamily, functions as a tumor suppressor by inhibit-
ing tumor cell motility, invasion, metastasis and angio-
genesis [12]. Maspin expression is aberrantly silenced in
many human cancers including breast, prostate, and
thyroid cancer. Nevertheless, in other malignancies such
as pancreatic, lung, and gastric cancer, maspin expres-
sion is increased in malignant cells compared to their
normal cells of origin [13]. In normal ovarian surface
epithelium the expression level of maspin is low while
ovarian cancer cell lines expressed high to low level of
maspin and maspin expression is correlated with shorter
survival in patients with epithelial ovarian cancer [14].
Ets factors have 200 known target genes, including
proteases (MMP-1, -3 and- 9, cathepsin) and their inhi-
bitors (TIMP-1), cell cycle molecules (Cyclin D1, p21),
regulators of apoptosis(Fas, RARP, Bcl-2, Bcl-XL), adhe-
sion molecules (E-cadherin, integrins), immune response
mediators (interleukins, immunoglobulins), and angio-
genesis mediators (VEGF receptors Flt-1, flk-1, Tie1 and
Tie2) [15]. It is proposed that Ets-1 functions upstream
of angiogenesis cascade, since many potent angiogenic
factors contain Ets binding sites in their promoter
regions. However, the relationship between Ets-1 and
some of its target genes involved in angiogenesis has
not been fully investigated in ovarian cancer. In the pre-
sent study, we examined the relationship between the
expression of Ets-1 and its targets Ang-2 and maspin in
ovarian cancer and their clinical significance.
Methods
Patients and tumor samples
All the specimens were obtained from surgical resection at
the 1
st and 4
th affiliated Hospital of Harbin Medical
University from 2007 to 2009. The 30 specimens included
21 cases of ovarian cancer and 9 cases of benign ovarian
tumor. The patients’ information was provided by the
pathology departments of the two hospitals, including the
age, pathological diagnosis, grade, stage, surgical process
and ascites status of each patient. The ovarian tumors
were paraffin embedded and fixed with 10% neutral for-
malin. Clinical stage was determined by criteria of FIGO.
The age of the patients ranged from 37 to 69 years old.
The study was approved by the Ethics Committee of
Harbin Medical University.
Immunohistochemical staining (IHC)
The ovarian tumors were paraffin embedded and fixed
with 10% neutral formalin. The samples were cut as
4-5 μm thick sections. Next the sections were deparaffi-
nized and the antigens were retrieved by steam treatment
in a citrate buffer, quenched for 10 min with 3% hydrogen
peroxide at room temperature. Then the expression of
Ets-1, Ang2, maspin and CD34 was assessed by IHC using
specific antibodies as follows: Ets-1 and Maspin (rabbit
anti human, 1:150 dilution) were from Santa Cruz Com-
pany (USA), Ang-2 (rabbit anti human, 1:100 dilution)
was from ABCam company (Shanghai, China), CD34
(clone QBEnd/10) was from Zhongshanjinqiao Biotech-
nology (Beijing, China). Then the slides were rinsed with
PBS and incubated with rabbit and rat serum polyclonal
antibody from Zhong Shan biological science and technol-
ogy ltd (Beijing, China) for 30 min at room temperature.
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for 15 min with 0.06% diaminobenzidine and counter-
stained with Harris modified hematoxylin. As negative
controls, the sections were incubated with PBS instead of
primary antibodies. CD34 immunostaining was used to
determine tumor MVD. The three most hypervascular
areas were selected under low power field. Any single
endothelial cell or cluster of endothelial cells identified by
positive CD34 staining was counted as a single microves-
sel. MVD was counted as the number of vessels per high-
power field (×200). The mean value for the three fields
was recorded as the MVD for each tumor sample.
Evaluation of immunohistochemical staining
Ovarian tumor specimens were categorized into groups by
percentage of the cells stained. In addition, staining inten-
sity was scored as 0 (negative), 1+ (weak), 2+ (medium),
and 3+ (strong). A combined score based on the staining
intensity and the percentage of cells stained was used to
assign a final score. We used ocular grid micrometer ruler
to calculate total cell count and positive staining cell count
according to McCarty [16], and expression rate (X) was
determined by the ratio of positive staining cells to total
cell count: the expression degree was defined as (-) if X <
10%; 1 + if 10%≦ X < 25%; 2 + if 25%≦X < 50%; 3 + if X ≧
50%. Each section was given a histoscore calculated by the
formula: Σ(i+1)×Pi (i stands for staining density; ranges
from 1 to 4, 0 means no staining; Pi stands for the percen-
tage of the cells stained) [9].
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences, version 17.0 (SPSS Inc, Chicago, IL,
USA). The Mann-Whitney U-test and Kruskal wallis H
test was used to compare the categorical variables
between the groups; Spearman rank correlation was
used to evaluate correlation analysis. P values < 0.05
were considered statistically significant.
Results
The expression of Ets-1, Ang-2 and maspin in ovarian
cancer
Immunohistochemistry staining showed that Ets-1 was
strongly expressed in cancer cells and stroma (Figure
1A) but weakly expressed in benign tumors (Figure 1B).
Ang-2 was mainly expressed in tumor stroma and had
similar expression pattern in malignant and benign
tumors (Figure 1C, D). Maspin expression was predomi-
nantly located in the cytoplasma and occasionally in the
nucleus of epithelium and cancer cells. The positive
expression rate of maspin in benign tumors was 55.56%
(5/9) while the rate in ovarian cancer was 52.38% (11/
21), there was no significant difference between the two
groups (Figure 1E, F).
The correlation between the expression of Ets-1, Ang-2
and maspin and the clinical manifestation of ovarian
cancer
Statistical analysis revealed that Ets-1 expression had no
obvious correlation with age, pathological types, grade,
stage and ascites formation, but had significant correla-
tion with malignancy of the tumor (Table 1). The expres-
sion of Ets-1 was much stronger in ovarian cancer than
benign tumors (p = 0.022). In contrast, Ang-2 and mas-
pin expression had no significant relationship with the
biological behaviors mentioned above. Correlation analy-
sis showed that Ets-1 had a positive correlation with
Ang-2 (p = 0.0436;r = 0.37728), as shown in Table 2, but
no significant correlation was found in multiple compari-
son among the three factors. CD34 staining was used to
evaluate MVD and MVD value had no obvious relation-
ship with the expression of the three proteins (Ets-1 and
MVD, p = 0.1456; Ang-2 and MVD, p = 0.2826; maspin
and MVD, p = 0.6203).
Discussion
Angiogenesis plays a key role in early embryo develop-
ment but is rarely found in the adult except in these
situations: response to cyclic hormone stimulation of
ovary and uterus; damage stress response and other
pathological situations such as tumorigenesis and dia-
betes [17]. Ets-1 expression is upregulated in endothelial
cells of neo-vessels during tumor angiogenesis [18].
Thus we hypothesized that Ets-1 expression may be
upregulated in ovarian cancer and contribute to ovarian
cancer development. Consistent with our hypothesis, in
this study we found that Ets-1 had a much stronger
expression in ovarian cancer than in benign tumor (p =
0.022), suggesting that Ets-1 is a potential factor that
contributes to ovarian cancer angiogenesis. Although a
study reported that Ets-1 expression had positive corre-
lation with stage, grade and poor prognosis of ovarian
cancer [19], our results showed that Ets-1 expression
had no significant relationship with stage and grade (p =
0.867 and 0.588, respectively). The difference may be
due to the relative small samples we surveyed.
With regard to Ang-2 expression, it has been
reported that Ang-2 and Tie2 expression had no statis-
tical difference between normal ovaries with corpus
luteum and ovarian cancer [17]. Our results showed
that Ang-2 expression had no obvious difference in
ovarian cancer and benign tumor (p = 0.892), consis-
tent with the previous report. We also found that
Ang-2 expression tended to be negative in poorly or
moderately differentiated ovarian cancer, although P
value failed to reach statistical meaning (P = 0.197).
Further study employing larger samples will help
define the correlation of Ang-2 expression with clinical
manifestation of ovarian cancer.
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but is down-regulated in infiltrating cancer and meta-
static lesion [20]. It was reported that loss of maspin
expression during tumor progression resulted from both
the absence of transactivation through the Ets element
and the presence of transcription repression through the
negative hormonal responsive element (HRE) recognized
by androgen receptor [21]. Zhang et al. found that two
transcription factors which bound to the promoter of
maspin, Ets and Ap1, showed functional incapacitation
in metastatic or infiltrative carcinoma [22]. Therefore,
we speculated that the reason for negative or weak
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Figure 1 Immunohistochemical staining for Ets-1, Ang-2 and Maspin in ovarian tumor tissues. A: Ets-1 expression in ovarian moderately
and poorly differentiated serous adenocarcinoma; B: Ets-1 expression in ovarian borderline mucinous cystadenoma; C: Ang-2 expression in left
ovarian serous papillary cystadenocarcinoma; D: Ang-2 expression in ovarian borderline mucinous cystadenoma; E: Maspin expression in
mucinous cystadenocarcinoma; F: Maspin expression in mucinous cystadenoma. The brown- colored particles deposition region shown in the
images stand for positive expression. Ang-2, Angiopoietin-2.
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to the dysfunction of Ets-1 which downregulated maspin
expression at transcription level although the expression
of Ets-1 was much stronger in ovarian cancer than
benign tumors. In this aspect, it is noteworthy that the
activity of maspin protein may be modulated by its sub-
cellular localization. Sood et al. found that 4 of 14
benign ovarian neoplasms expressed maspin with mostly
nuclear localization; 8 of 10 low malignant potential
ovarian tumors had mostly nuclear staining; but only 15
of 57 ovarian cancer had predominant nuclear staining
[23]. Our results showed that weak positive expression
of maspin in the nucleus appeared only in benign
tumors while cytoplasmic strong positive expression was
predominantly found in ovarian cancer. In addition, all
the 3 cases of cytoplasmic expression of maspin in ovar-
ian cancers were high grade with higher MVD value
compared with benign tumors, which was in accordance
with previous studies. The mechanisms underlying the
localization of maspin and its interaction with Ets-1
warrant further investigations.
In this study we employed IHC to evaluate the expres-
sion of Ets-1, Ang-2 and maspin in clinical samples of
ovarian cancer. While IHC is an excellent detection
technique widely used to understand the distribution
and localization of biomarkers and differentially
expressed proteins in different parts of tissue samples.
Its major disadvantage is that it is impossible to show
that the staining corresponds with the protein of interest
as in the case of immunoblotting techniques where
staining is checked against a molecular weight ladder.
For this reason, primary antibodies must be validated by
Western Blot before it can be used for IHC. In this
study the antibodies for Ets-1, Ang-2 and maspin were
commercially derived and validated, and their specificity
is warranted.
Conclusions
In conclusion, our data show that Ets-1 expression was
much stronger in ovarian cancer than benign tumors; it
had no significant correlation with other biological
behaviors, such as grade, stage and ascites. Ang-2 and
maspin expression showed no close relationship with
biological behaviors mentioned above. Ang-2 had similar
expression pattern in ovarian cancer and benign tumors
and may be related to vasculature stability during angio-
genesis rather than other features of ovarian cancer. Ets-
1 had positive correlation with Ang-2 which showed
their close relationship in angiogenesis. Maspin expres-
sion tended to be determined by subcellular localization
and strong nuclear expression of maspin appears to be
correlated with high grade and MVD. The connections
a m o n gt h et h r e ea n g i o g e n i cf a c t o r sE t s - 1 ,A n g - 2a n d
Maspin need future study and the mechanisms by which
these factors crosstalk will provide us new therapeutic
interventions for ovarian cancer.
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